Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) was $15.1 for the day, down -1.63% from the previous closing price of $15.35. In other words, the price has decreased by -$1.63 from its previous closing price. On the day, 3.36 million shares were traded. SNDX stock price reached its highest trading level at $15.29 during the session, while it also had its lowest trading level at $14.2668.
Ratios:
Our analysis of SNDX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.42 and its Current Ratio is at 4.64. In the meantime, Its Debt-to-Equity ratio is 2.99 whereas as Long-Term Debt/Eq ratio is at 2.79.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 08 ’25 when Metzger Michael A sold 157,307 shares for $16.41 per share. The transaction valued at 2,582,021 led to the insider holds 298,661 shares of the business.
MICHAEL METZGER bought 157,307 shares of SNDX for $2,680,511 on Sep 08 ’25. On Aug 18 ’25, another insider, Podlesak Dennis, who serves as the Director of the company, sold 19,200 shares for $15.84 each. As a result, the insider received 304,170 and left with 191,763 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SNDX now has a Market Capitalization of 1312414080 and an Enterprise Value of 1203671040. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.77 while its Price-to-Book (P/B) ratio in mrq is 11.37. Its current Enterprise Value per Revenue stands at 10.814 whereas that against EBITDA is -3.922.
Stock Price History:
The Beta on a monthly basis for SNDX is 0.49, which has changed by -0.28671002 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, SNDX has reached a high of $22.50, while it has fallen to a 52-week low of $8.58. The 50-Day Moving Average of the stock is -1.31%, while the 200-Day Moving Average is calculated to be 16.42%.
Shares Statistics:
SNDX traded an average of 2.84M shares per day over the past three months and 4808000 shares per day over the past ten days. A total of 86.91M shares are outstanding, with a floating share count of 84.09M. Insiders hold about 3.25% of the company’s shares, while institutions hold 120.87% stake in the company. Shares short for SNDX as of 1760486400 were 22023042 with a Short Ratio of 7.76, compared to 1757894400 on 23141658. Therefore, it implies a Short% of Shares Outstanding of 22023042 and a Short% of Float of 28.87.
Earnings Estimates
Current recommendations for the stock of the company come from 12.0 analysts. The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.43 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$2.16 and -$3.42 for the fiscal current year, implying an average EPS of -$3.04. EPS for the following year is -$1.46, with 12.0 analysts recommending between -$0.51 and -$3.01.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 9 analysts. It ranges from a high estimate of $76.6M to a low estimate of $57M. As of. The current estimate, Syndax Pharmaceuticals Inc’s year-ago sales were $7.68MFor the next quarter, 9 analysts are estimating revenue of $75.48M. There is a high estimate of $90.46M for the next quarter, whereas the lowest estimate is $61M.
A total of 9 analysts have provided revenue estimates for SNDX’s current fiscal year. The highest revenue estimate was $180.5M, while the lowest revenue estimate was $160.1M, resulting in an average revenue estimate of $170.4M. In the same quarter a year ago, actual revenue was $23.68MBased on 12 analysts’ estimates, the company’s revenue will be $376.6M in the next fiscal year. The high estimate is $474.48M and the low estimate is $288.5M.
